Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease

Table 1 Baseline clinical characteristics of patients with intestinal Behcet’s disease

Characteristic	No. of patient (%)
Age at diagnosis of BD (yr)	38.5 ± 12.2
Age at diagnosis of intestinal BD (yr)	41.4 ± 12.3
Gender (male:female)	71:96 (42.5:57.5)
Systemic symptoms and signs of BD
Recurrent oral ulcer	159 (95.2)
Recurrent genital ulcer	78 (46.7)
Ocular lesion	10 (6.0)
Skin lesion	82 (49.1)
Positive pathergy test	4 (2.4)
Arthritis or arthralgia	66 (39.5)
Neurologic lesion	0
Vascular lesion	2 (1.2)
Clinical subtype of BD
Complete	3 (1.8)
Incomplete	78 (46.7)
Suspected	53 (31.7)
Symptoms and signs of intestinal involvement
Abdominal pain	120 (71.8)
Diarrhea	142 (85.0)
Abdominal mass	4 (2.4)
Tenderness	119 (71.2)
Nausea/vomiting	4 (2.4)
Melena/hematochezia	31 (18.6)
Fistula	4 (2.4)
Stenosis (intestinal obstruction)	10 (6.0)
Abscess	0
Perforation	0
Current use of medication
5-ASA or sulfasalazine	163 (97.6)
Azathioprine or 6-mercaptopurine	24 (14.4)
Colchicine	80 (47.9)
Corticosteroid	72 (43.1)
Patient global assessment
Well	63 (37.7)
Mild	53 (31.7)
Moderate	45 (26.9)
Severe	6 (3.6)
DAIBD	74.9 ± 36.1 (5-155)
Quiescent ( ≤ 19)	2 (1.2)
Mild (20-39)	32 (19.2)
Moderate (40-74)	50 (29.9)
Severe (≥ 75)	83 (49.7)

BD: Behcet’s disease; DAIBD: Disease activity index for intestinal Behcet’s disease; 5-ASA: 5-aminosalicylic acid.